Adjuvant chemotherapy improves OS in UTUC

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-02-22 DOI:10.1038/s41571-024-00875-1

David Killock

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

辅助化疗可改善UTUC的OS

2020年，根据POUT试验的无病生存期（DFS）数据，铂类辅助化疗成为输尿管或肾盂上段尿路上皮癌（UTUC）肌浸润或局部晚期患者的标准治疗方法。在这项III期试验中，261名切除的肌层浸润性或结节阳性UTUC患者被1:1随机分配接受四个周期的吉西他滨加顺铂或卡铂辅助治疗，或单独接受监测。中位随访时间为30个月后，DFS的主要终点达到（3年DFS为71%对46%；HR为0.45，95% CI为0.30-0.68；P = 0.0001），于是停止注册，进一步降低了OS分析的统计能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.